The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Site Search
Showing 1 - 3 of 3 results
Press Release
|
March 29, 2022
|
4 min read
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
Press Release
|
Jan. 4, 2022
|
4 min read
The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Press Release
|
April 3, 2024
|
3 min read